OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Application Site Vesicles reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 6,432 reports · 48 co-occurring drugs

As of the last recalculation, Application Site Vesicles appears in 6,432 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is BUPRENORPHINE (PRR 42.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Buprenorphine1,02442.442.9
Nicotine30825.826.0
Rotigotine9020.420.5
Glycerin, Lidocaine8720.420.5
Docosanol8719.519.6
Methylphenidate10311.711.7
Minoxidil Foam 5% (Womens)11111.111.1
Estradiol28010.911.0
Nicotine Polacrilex Mini5010.910.9
Nicotine Polarilex5010.910.9
Minoxidil14210.410.5
Crisaborole289.59.5
Nicotine Polacrilex1069.19.1
Estradiol Gel 0.1%896.46.5
Estradiol Transdermal896.46.5
Oxybutynin505.65.6
Rivastigmine325.55.5
Clonidine825.25.2
Fentanyl Citrate193.43.5
Epoprostenol133.23.2
Tretinoin83.23.2
Fentanyl963.23.2
Clobetasol Propionate Ointment Usp, 0.05%92.82.8
Clobetasol Propionate92.82.8
Granisetron92.82.8
Lidocaine, Menthol422.82.8
Gentamicin112.72.7
Testosterone192.62.6
Miconazole Nitrate72.62.6
Diclofenac Sodium1152.52.5
Lidocaine442.52.5
Ketoconazole132.42.4
Ketoconazole Cream, 2%112.42.4
Diclofenac Sodium 1%262.42.4
Diclofenac Sodium Topical262.42.4
Diclofenac Sodium Topical Gel, 1%262.42.4
Tizanidine Hydrochloride132.32.3
Gentamicin Sulfate112.32.3
Ketoconazole Foam102.22.2
Terbinafine Hydrochloride51.81.8
Buprenorphine Hydrochloride, Naloxone Hydrochloride121.61.6
Asenapine Maleate41.51.5
Travoprost31.11.1
Vilazodone Hydrochloride31.11.1
Onabotulinumtoxina170.70.7
Salicylic Acid100.60.6
Pegfilgrastim160.50.5
Etonogestrel50.30.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.